title: Isolated left ventricular filling abnormalities may predict interleukin-2-induced cardiovascular toxicity.
abstract: Interleukin-2 (IL-2) is a cytokine with proven activity against metastatic renal cell carcinoma (RCC) and malignant melanoma (MM). The intravenous administration of high-dose IL-2 is limited by important cardiovascular side effects such as hypotension, fluid retention, arrhythmias, and myocardial ischemia, which often cause dose reduction and/or treatment withdrawal. The occurrence of these toxic events is not predicted by routine pretreatment examinations. The aim of the present study was to test the reliability of serial echocardiography in predicting subsequent cardiac adverse effects in patients undergoing IL-2 administration. In 19 patients (15 men, 4 women; median age: 51 years, range 27-71 years; 10 affected by metastatic RCC and 9 affected by MM) we performed two-dimensional and Doppler echocardiography before and immediately after 28 continuous intravenous infusions (CIVI) of IL-2 at the dose of 18 MIU/m2/day for 4 days. Left ventricular systolic function and the diastolic transmitral flow pattern were assessed before and after IL-2 administration. Significant changes of two indexes of left ventricular filling were noted: a decrease of the ratio of maximal flow velocity in early diastole to that in late diastole (E/A) (basal: 1.12 +/- 0.46, mean +/- SD; posttreatment: 0.83 +/- 0.27; p < 0.01) and an increase of the percentage of the atrial contribution to left ventricular filling (basal: 37.75 +/- 11.58%; posttreatment: 49.43 +/- 16.48%; p < 0.01). Eight major cardiovascular events causing IL-2 infusion withdrawal were observed (two ischemic electrocardiographic modifications, three grade III-IV hypotension, one atrial fibrillation, one pericardial effusion, one acute heart failure). These major cardiovascular events were observed more often when an abnormal basal E/A ratio < 1.0 (p < 0.05) was found. We conclude that Doppler transmitral flow pattern analysis before and subsequent to IL-2 infusion is a useful and easily available procedure for the monitoring of cardiac modifications during CIVI IL-2 administration. It might also predict a major cardiovascular event during IL-2 administration. Patients with basal E/A ratio < 1.0 should be more carefully monitored during treatment and/or should be treated with lower IL-2 doses to avoid cardiovascular toxicity.
authors.affiliation: Divisione di Medicina II, IRCCS H S. Raffaele, Milan, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Citterio
authors.forename: G
authors.initials: G
authors.lastname: Fragasso
authors.forename: E
authors.initials: E
authors.lastname: Rossetti
authors.forename: G
authors.initials: G
authors.lastname: Di Lucca
authors.forename: E
authors.initials: E
authors.lastname: Bucci
authors.forename: M
authors.initials: M
authors.lastname: Foppoli
authors.forename: R
authors.initials: R
authors.lastname: Guerrieri
authors.forename: P
authors.initials: P
authors.lastname: Matteucci
authors.forename: D
authors.initials: D
authors.lastname: Polastri
authors.forename: U
authors.initials: U
authors.lastname: Scaglietti
authors.forename: M
authors.initials: M
authors.lastname: Tresoldi
authors.forename: S L
authors.initials: SL
authors.lastname: Chierchia
authors.forename: C
authors.initials: C
authors.lastname: Rugarli
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000628:therapy; D015150:Echocardiography, Doppler; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D018487:Ventricular Dysfunction, Left / Q000209:etiology* / Q000503:physiopathology*
chemical_list: D015415:Biomarkers; D007376:Interleukin-2